HPV Infection Affects Over One in Ten Women Screened in Northern China, Study Finds

A large cross-sectional study from Shanxi Province in northern China has provided one of the most detailed baselines yet of human papillomavirus (HPV) infection and cervical cytological abnormalities among women attending routine health examinations. Drawing on clinical data collected from 19,384 women between January 2021 and December 2024, researchers affiliated with Shanxi Medical University found that high-risk HPV prevalence stood at 10.9 percent, with HPV52, HPV16 and HPV58 emerging as the most frequently detected genotypes. The findings arrive at a pivotal moment: in November 2025, HPV vaccination was incorporated into China’s national immunization programme, and robust pre-vaccination epidemiological data of this kind are exactly what public health authorities need to measure the vaccine’s downstream impact and to refine screening strategies.

The study, published as an open-access research article in Virology Journal, is notable for combining HPV DNA testing with concurrent cervical cytology in a single, large cohort. Women undergoing routine health examinations at participating facilities provided cervical samples for HPV genotyping and ThinPrep cytologic testing. The cohort had a median age of 42 years, with an interquartile range of 36 to 51 years, placing most participants squarely within the age band where cervical cancer screening is most actively recommended. By pairing molecular virology with cytological classification, the researchers were able to map how individual viral genotypes distribute themselves across the spectrum of cervical abnormalities, from benign findings to high-grade lesions.

HPV is a double-stranded DNA virus with more than 200 known genotypes, of which roughly a dozen, designated high-risk types, are established causes of cervical cancer. Persistent infection with HPV16 and HPV18 accounts for the majority of cervical cancer cases worldwide, which is why these two genotypes anchor the bivalent and quadrivalent vaccines, while the nonavalent formulation extends coverage to HPV31, 33, 45, 52 and 58. The Shanxi data confirm that the regional genotype landscape does not perfectly mirror the global one. HPV52 was the single most prevalent high-risk genotype at 2.3 percent, ahead of HPV16 and HPV58, each at 1.7 percent. Combined prevalence of HPV16 and HPV18 was 2.3 percent, while the nine genotypes covered by the nonavalent vaccine collectively accounted for 7.4 percent of infections, meaning roughly two-thirds of high-risk infections in this population fall within the nonavalent vaccine’s protective umbrella.

Beyond genotype frequencies, the researchers used multivariable logistic regression to isolate risk factors associated with high-risk HPV infection. Age emerged as a strong and independent determinant. Compared with women aged 20 to 35 years, those aged 56 to 65 years had roughly twice the odds of carrying a high-risk infection, with an adjusted odds ratio of 2.0 and a 95 percent confidence interval of 1.6 to 2.3. This pattern is consistent with a recognized second peak of HPV prevalence among older women, often attributed to reactivation of previously acquired latent infections, declining immune surveillance after menopause, or cohort effects related to sexual behavior and screening history in older generations. Marital status also carried a signal: married women had about half the odds of high-risk HPV infection compared with unmarried women, an adjusted odds ratio of 0.5 with a confidence interval of 0.4 to 0.7, a finding the authors report without overinterpreting its behavioral or social underpinnings.

Cytological abnormalities were far less common than viral infections overall. Abnormal cytology was detected in 2.1 percent of the 19,384 participants, spanning the full range of the Bethesda classification system, from atypical squamous cells of undetermined significance through low-grade and high-grade squamous intraepithelial lesions. The relatively low rate of abnormal cytology reflects the natural history of HPV disease: most infections are transient and cleared by cell-mediated immunity within one to two years, and only a small fraction of persistent infections progress through cytological change toward malignancy. This biological bottleneck is precisely what makes genotype-specific surveillance valuable, because identifying which viral types are enriched among abnormal cytology results sharpens the predictive value of screening.

The most striking analytical finding concerns how genotype composition shifts with lesion severity. Among HPV-positive women, the prevalence of HPV16 and HPV18 rose significantly as cytological grade increased, with a 3.4-fold higher odds of these two genotypes in atypical squamous cells cannot exclude high-grade lesion or high-grade squamous intraepithelial lesion categories compared with low-grade lesions, at an odds ratio of 3.4 and a confidence interval of 1.0 to 11.5. The genotypes HPV31, 33, 45, 52 and 58 showed a moderate but statistically non-significant increase across severity strata, with an odds ratio of 1.8 and a confidence interval spanning 0.6 to 5.6. Meanwhile, high-risk genotypes outside this seven-type group actually declined in prevalence as lesions became more severe, with an odds ratio of 0.6 and a confidence interval of 0.1 to 2.2. In other words, the viral population underlying mild abnormalities is more heterogeneous, whereas severe lesions concentrate around the genotypes with established oncogenic potency.

From a virological standpoint, this gradient makes mechanistic sense. HPV16, and to a lesser extent HPV18, carry sequence variations in the E6 and E7 oncogenes and in regulatory regions that favor expression of proteins which degrade the p53 and retinoblastoma tumor suppressor pathways. Viruses equipped with these features are more likely to escape cell-cycle control long enough for a lesion to progress, which is why they dominate the high-grade end of the spectrum even when other genotypes are more common among transient infections. HPV52 and HPV58, both classified as high-risk and both notably prevalent in East Asian populations, appear to occupy an intermediate position, contributing substantially to infection burden and to lesions, but with a weaker per-infection association with severe cytology than HPV16/18 in this dataset.

The timing of these findings amplifies their policy relevance. China’s decision to introduce HPV vaccination into its national immunization programme in November 2025 created an urgent need for baseline genotype distribution data across representative provinces. Without such baselines, it would be difficult to distinguish vaccine-driven changes in genotype prevalence from natural fluctuations. The Shanxi results suggest that bivalent and quadrivalent vaccination, which target HPV16 and HPV18 plus HPV6 and 11 in the quadrivalent formulation, will directly address only about one-fifth of the high-risk infections observed here, while nonavalent vaccination would cover roughly two-thirds. At the same time, the significant enrichment of HPV16/18 among high-grade lesions means those two genotypes still account for a disproportionate share of the abnormalities most likely to progress toward cancer, so even narrower vaccines should deliver outsized reductions in cancer incidence.

The authors emphasize that their data support genotype-specific risk assessment as a pillar of future cervical cancer prevention in China. As vaccination scales up, screening programmes may need to adapt, potentially shifting toward HPV-based primary screening with genotyping for HPV16 and HPV18, followed by reflex cytology, a triage algorithm already adopted in many high-income settings. The observed age-related rise in prevalence also cautions against focusing vaccination and screening exclusively on younger cohorts; older women, who are largely beyond catch-up vaccination eligibility, will continue to carry a substantial burden of infection for decades and will remain dependent on effective cytological or molecular screening. The finding that married women had lower infection odds, whatever its underlying behavioral explanation, may help target health education and screening outreach toward demographic groups with higher observed risk.

As with all cross-sectional designs, the study captures a single snapshot in time and cannot establish whether infections preceded cytological changes, nor can it follow individuals to confirm clearance or progression. The participant pool, drawn from women presenting for routine health examinations, may also skew toward populations with better healthcare access than the general provincial population. Nevertheless, with nearly twenty thousand paired HPV and cytology results, the study offers an unusually granular portrait of HPV epidemiology in a region of China where such data had been limited. As the national vaccination programme matures, repeated iterations of this kind of surveillance in Shanxi and comparable provinces will be essential for verifying whether the vaccine is bending the genotype distribution curve, reducing cytological abnormalities, and ultimately accelerating China’s progress toward the World Health Organization’s cervical cancer elimination targets.

Subject of Research: Prevalence, genotype distribution and risk factors of human papillomavirus infection and cervical cytological abnormalities among women in Shanxi, China

Article Title: Prevalence and risk factors of human papillomavirus infection and cervical cytological lesions among women in Shanxi, China: a cross-sectional study

Article References: Ge, S., Gao, H., Wang, J., Guo, S., Chang, Y., Qi, Y., Han, J., Jia, Y., Dong, J., & Wei, F. (2026). Prevalence and risk factors of human papillomavirus infection and cervical cytological lesions among women in Shanxi, China: a cross-sectional study. Virology Journal. https://doi.org/10.1186/s12985-026-03300-4

Image Credits: AI Generated

DOI: 10.1186/s12985-026-03300-4

Keywords: human papillomavirus, HPV prevalence, HPV52, HPV16, HPV58, cervical cytology, cervical cancer, genotype distribution, high-risk HPV, cross-sectional study, Shanxi China, HPV vaccination